IL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in RAS mutant metastatic colorectal cancer patients

Mariantonietta Di Salvatore, Filippo Pietrantonio, Armando Orlandi, Marzia Del Re, Rosa Berenato, Ernesto Rossi, Marta Caporale, Donatella Guarino, Antonia Martinetti, Michele Basso, Roberta Mennitto, Concetta Santonocito, Alessia Mennitto, Giovanni Schinzari, Ilaria Bossi, Ettore Capoluongo, Romano Danesi, Filippo de Braud, Carlo Barone

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background: Predictive biomarkers of efficacy and toxicity of bevacizumab have not yet been validated. This study assessed the influence of IL-8, eNOS and VEGF-A polymorphisms in RAS mutated metastatic colorectal cancer patients receiving bevacizumab-based chemotherapy. Methods: 120 patients treated with first-line combination FOLFOX6 plus bevacizumab were included. A historical cohort of 112 RAS mutated colorectal cancer patients treated with FOLFOX6 alone served as control group. The following SNPs were analyzed: IL-8 c.-251T>A; eNOS c.-786T>C and c.-894G>T; VEGF-A c.936C>T, c.958T>C, c.1154A>G and c.2578C>A. Correlation of SNPs, baseline IL-8 serum levels and bevacizumab-efficacy was done. Results: In the bevacizumab group, carriers of the IL-8 alleles c.-251TA+AA showed a shorter PFS (P=0.002) and OS (P=0.03) compared to TT alleles. Patients with pre-treatment IL-8 < 18.25 pg/ml showed significantly longer median PFS and OS (PFS: 10.9 vs 7.6 months, P=0.005; OS: 30.7 vs 18.2 months, P < 0.001) compared to patients with IL-8 higher levels (>18,25 pg/ml). IL-8 c.-251TA+AA carriers had significantly higher IL-8 levels (P < 0.0001). Multivariate analysis confirmed association of IL-8 polymorphism with PFS, and of IL-8 baseline levels with both PFS and OS. IL-8 SNP did not affect the outcome in the control group. The eNOS polymorphism c.-894G>T was found associated with higher severe toxicity (P=0.0002) in patients carrying the c.-894TT genotype. Conclusions: Although our data need prospective validation, IL-8 and eNOS SNPs may be have a role as predictive biomarkers for bevacizumab efficacy and toxicity.

Original languageEnglish
Pages (from-to)16887-16898
Number of pages12
JournalOncotarget
Volume8
Issue number10
DOIs
Publication statusPublished - Jan 1 2017

Fingerprint

Interleukin-8
Colorectal Neoplasms
Single Nucleotide Polymorphism
Vascular Endothelial Growth Factor A
Biomarkers
Alleles
Interleukin-18
Bevacizumab
Genotype
Drug Therapy
Control Groups
Serum

Keywords

  • Bevacizumab
  • Colorectal cancer
  • ENOS
  • IL-8
  • Single nucleotid polymorphisms

ASJC Scopus subject areas

  • Oncology

Cite this

Di Salvatore, M., Pietrantonio, F., Orlandi, A., Del Re, M., Berenato, R., Rossi, E., ... Barone, C. (2017). IL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in RAS mutant metastatic colorectal cancer patients. Oncotarget, 8(10), 16887-16898. https://doi.org/10.18632/oncotarget.14810

IL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in RAS mutant metastatic colorectal cancer patients. / Di Salvatore, Mariantonietta; Pietrantonio, Filippo; Orlandi, Armando; Del Re, Marzia; Berenato, Rosa; Rossi, Ernesto; Caporale, Marta; Guarino, Donatella; Martinetti, Antonia; Basso, Michele; Mennitto, Roberta; Santonocito, Concetta; Mennitto, Alessia; Schinzari, Giovanni; Bossi, Ilaria; Capoluongo, Ettore; Danesi, Romano; de Braud, Filippo; Barone, Carlo.

In: Oncotarget, Vol. 8, No. 10, 01.01.2017, p. 16887-16898.

Research output: Contribution to journalArticle

Di Salvatore, M, Pietrantonio, F, Orlandi, A, Del Re, M, Berenato, R, Rossi, E, Caporale, M, Guarino, D, Martinetti, A, Basso, M, Mennitto, R, Santonocito, C, Mennitto, A, Schinzari, G, Bossi, I, Capoluongo, E, Danesi, R, de Braud, F & Barone, C 2017, 'IL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in RAS mutant metastatic colorectal cancer patients', Oncotarget, vol. 8, no. 10, pp. 16887-16898. https://doi.org/10.18632/oncotarget.14810
Di Salvatore, Mariantonietta ; Pietrantonio, Filippo ; Orlandi, Armando ; Del Re, Marzia ; Berenato, Rosa ; Rossi, Ernesto ; Caporale, Marta ; Guarino, Donatella ; Martinetti, Antonia ; Basso, Michele ; Mennitto, Roberta ; Santonocito, Concetta ; Mennitto, Alessia ; Schinzari, Giovanni ; Bossi, Ilaria ; Capoluongo, Ettore ; Danesi, Romano ; de Braud, Filippo ; Barone, Carlo. / IL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in RAS mutant metastatic colorectal cancer patients. In: Oncotarget. 2017 ; Vol. 8, No. 10. pp. 16887-16898.
@article{8470ef7b4dba420d80a7d61813235f21,
title = "IL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in RAS mutant metastatic colorectal cancer patients",
abstract = "Background: Predictive biomarkers of efficacy and toxicity of bevacizumab have not yet been validated. This study assessed the influence of IL-8, eNOS and VEGF-A polymorphisms in RAS mutated metastatic colorectal cancer patients receiving bevacizumab-based chemotherapy. Methods: 120 patients treated with first-line combination FOLFOX6 plus bevacizumab were included. A historical cohort of 112 RAS mutated colorectal cancer patients treated with FOLFOX6 alone served as control group. The following SNPs were analyzed: IL-8 c.-251T>A; eNOS c.-786T>C and c.-894G>T; VEGF-A c.936C>T, c.958T>C, c.1154A>G and c.2578C>A. Correlation of SNPs, baseline IL-8 serum levels and bevacizumab-efficacy was done. Results: In the bevacizumab group, carriers of the IL-8 alleles c.-251TA+AA showed a shorter PFS (P=0.002) and OS (P=0.03) compared to TT alleles. Patients with pre-treatment IL-8 < 18.25 pg/ml showed significantly longer median PFS and OS (PFS: 10.9 vs 7.6 months, P=0.005; OS: 30.7 vs 18.2 months, P < 0.001) compared to patients with IL-8 higher levels (>18,25 pg/ml). IL-8 c.-251TA+AA carriers had significantly higher IL-8 levels (P < 0.0001). Multivariate analysis confirmed association of IL-8 polymorphism with PFS, and of IL-8 baseline levels with both PFS and OS. IL-8 SNP did not affect the outcome in the control group. The eNOS polymorphism c.-894G>T was found associated with higher severe toxicity (P=0.0002) in patients carrying the c.-894TT genotype. Conclusions: Although our data need prospective validation, IL-8 and eNOS SNPs may be have a role as predictive biomarkers for bevacizumab efficacy and toxicity.",
keywords = "Bevacizumab, Colorectal cancer, ENOS, IL-8, Single nucleotid polymorphisms",
author = "{Di Salvatore}, Mariantonietta and Filippo Pietrantonio and Armando Orlandi and {Del Re}, Marzia and Rosa Berenato and Ernesto Rossi and Marta Caporale and Donatella Guarino and Antonia Martinetti and Michele Basso and Roberta Mennitto and Concetta Santonocito and Alessia Mennitto and Giovanni Schinzari and Ilaria Bossi and Ettore Capoluongo and Romano Danesi and {de Braud}, Filippo and Carlo Barone",
year = "2017",
month = "1",
day = "1",
doi = "10.18632/oncotarget.14810",
language = "English",
volume = "8",
pages = "16887--16898",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "10",

}

TY - JOUR

T1 - IL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in RAS mutant metastatic colorectal cancer patients

AU - Di Salvatore, Mariantonietta

AU - Pietrantonio, Filippo

AU - Orlandi, Armando

AU - Del Re, Marzia

AU - Berenato, Rosa

AU - Rossi, Ernesto

AU - Caporale, Marta

AU - Guarino, Donatella

AU - Martinetti, Antonia

AU - Basso, Michele

AU - Mennitto, Roberta

AU - Santonocito, Concetta

AU - Mennitto, Alessia

AU - Schinzari, Giovanni

AU - Bossi, Ilaria

AU - Capoluongo, Ettore

AU - Danesi, Romano

AU - de Braud, Filippo

AU - Barone, Carlo

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Background: Predictive biomarkers of efficacy and toxicity of bevacizumab have not yet been validated. This study assessed the influence of IL-8, eNOS and VEGF-A polymorphisms in RAS mutated metastatic colorectal cancer patients receiving bevacizumab-based chemotherapy. Methods: 120 patients treated with first-line combination FOLFOX6 plus bevacizumab were included. A historical cohort of 112 RAS mutated colorectal cancer patients treated with FOLFOX6 alone served as control group. The following SNPs were analyzed: IL-8 c.-251T>A; eNOS c.-786T>C and c.-894G>T; VEGF-A c.936C>T, c.958T>C, c.1154A>G and c.2578C>A. Correlation of SNPs, baseline IL-8 serum levels and bevacizumab-efficacy was done. Results: In the bevacizumab group, carriers of the IL-8 alleles c.-251TA+AA showed a shorter PFS (P=0.002) and OS (P=0.03) compared to TT alleles. Patients with pre-treatment IL-8 < 18.25 pg/ml showed significantly longer median PFS and OS (PFS: 10.9 vs 7.6 months, P=0.005; OS: 30.7 vs 18.2 months, P < 0.001) compared to patients with IL-8 higher levels (>18,25 pg/ml). IL-8 c.-251TA+AA carriers had significantly higher IL-8 levels (P < 0.0001). Multivariate analysis confirmed association of IL-8 polymorphism with PFS, and of IL-8 baseline levels with both PFS and OS. IL-8 SNP did not affect the outcome in the control group. The eNOS polymorphism c.-894G>T was found associated with higher severe toxicity (P=0.0002) in patients carrying the c.-894TT genotype. Conclusions: Although our data need prospective validation, IL-8 and eNOS SNPs may be have a role as predictive biomarkers for bevacizumab efficacy and toxicity.

AB - Background: Predictive biomarkers of efficacy and toxicity of bevacizumab have not yet been validated. This study assessed the influence of IL-8, eNOS and VEGF-A polymorphisms in RAS mutated metastatic colorectal cancer patients receiving bevacizumab-based chemotherapy. Methods: 120 patients treated with first-line combination FOLFOX6 plus bevacizumab were included. A historical cohort of 112 RAS mutated colorectal cancer patients treated with FOLFOX6 alone served as control group. The following SNPs were analyzed: IL-8 c.-251T>A; eNOS c.-786T>C and c.-894G>T; VEGF-A c.936C>T, c.958T>C, c.1154A>G and c.2578C>A. Correlation of SNPs, baseline IL-8 serum levels and bevacizumab-efficacy was done. Results: In the bevacizumab group, carriers of the IL-8 alleles c.-251TA+AA showed a shorter PFS (P=0.002) and OS (P=0.03) compared to TT alleles. Patients with pre-treatment IL-8 < 18.25 pg/ml showed significantly longer median PFS and OS (PFS: 10.9 vs 7.6 months, P=0.005; OS: 30.7 vs 18.2 months, P < 0.001) compared to patients with IL-8 higher levels (>18,25 pg/ml). IL-8 c.-251TA+AA carriers had significantly higher IL-8 levels (P < 0.0001). Multivariate analysis confirmed association of IL-8 polymorphism with PFS, and of IL-8 baseline levels with both PFS and OS. IL-8 SNP did not affect the outcome in the control group. The eNOS polymorphism c.-894G>T was found associated with higher severe toxicity (P=0.0002) in patients carrying the c.-894TT genotype. Conclusions: Although our data need prospective validation, IL-8 and eNOS SNPs may be have a role as predictive biomarkers for bevacizumab efficacy and toxicity.

KW - Bevacizumab

KW - Colorectal cancer

KW - ENOS

KW - IL-8

KW - Single nucleotid polymorphisms

UR - http://www.scopus.com/inward/record.url?scp=85014699212&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014699212&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.14810

DO - 10.18632/oncotarget.14810

M3 - Article

VL - 8

SP - 16887

EP - 16898

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 10

ER -